Quantum-Si Announces $50M Registered Direct Offering of Common Stock
ByAinvest
Monday, Jul 7, 2025 5:17 pm ET1min read
MORN--
The proceeds from the offering will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering, which is being made pursuant to an effective shelf registration statement on Form S-3 [1].
This announcement follows the company's mission to transform proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The platform enables real-time kinetic-based detection, allowing researchers to access dynamic, functional protein insights with unparalleled resolution [1].
Quantum-Si's forward-looking statements include expectations regarding future performance, data and product launches, and investor confidence. However, the company cautions that actual results may differ from these expectations due to various risks and uncertainties, including regulatory changes, competition, and market conditions [1].
Investors interested in more information can contact Jeff Keyes, Chief Financial Officer, at ir@quantum-si.com, or Katherine Atkinson, SVP, Commercial Marketing, at media@quantum-si.com.
References:
[1] https://www.morningstar.com/news/business-wire/20250703705354/quantum-si-incorporated-announces-pricing-of-50-million-registered-direct-offering-of-common-stock
QSI--
Quantum-Si Incorporated has announced the pricing of a $50 million registered direct offering of common stock. The offering involves the sale of 29,940,119 shares at $1.67 per share to a single institutional investor. The closing of the offering is expected on July 8, 2025. The proceeds will be used for working capital and general corporate purposes.
Quantum-Si Incorporated (Nasdaq: QSI), a proteomics technology company, has announced the pricing of a $50 million registered direct offering of common stock. The offering involves the sale of 29,940,119 shares at $1.67 per share to a single institutional investor. The closing of the offering is expected on July 8, 2025, subject to customary closing conditions [1].The proceeds from the offering will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering, which is being made pursuant to an effective shelf registration statement on Form S-3 [1].
This announcement follows the company's mission to transform proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The platform enables real-time kinetic-based detection, allowing researchers to access dynamic, functional protein insights with unparalleled resolution [1].
Quantum-Si's forward-looking statements include expectations regarding future performance, data and product launches, and investor confidence. However, the company cautions that actual results may differ from these expectations due to various risks and uncertainties, including regulatory changes, competition, and market conditions [1].
Investors interested in more information can contact Jeff Keyes, Chief Financial Officer, at ir@quantum-si.com, or Katherine Atkinson, SVP, Commercial Marketing, at media@quantum-si.com.
References:
[1] https://www.morningstar.com/news/business-wire/20250703705354/quantum-si-incorporated-announces-pricing-of-50-million-registered-direct-offering-of-common-stock
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet